For over a century, science believed only one part of your immune system could remember a threat. In 2011, everything changed. A discovery so fundamental it rewrote the textbooks — and may rewrite how we treat cancer, infections, and inflammatory disease.
"The innate immune system was supposed to be dumb. Fast, blunt, and forgetful. We were wrong."
Your immune system has two branches. The Adaptive immune system is the one you've heard of — it learns, remembers, and is why vaccines work. It produces antibodies and trains T cells to recognize specific invaders. This process takes days or weeks, but once done, the memory lasts a lifetime.
Then there's the Innate immune system — the first responder. It hits immediately, within minutes. It doesn't care what the threat is. It sees "foreign" and attacks. It was powerful, but according to 100 years of immunology, it was also stateless. No memory. No learning. Same response every single time.
This was taught in every medical school on earth. It was written in every immunology textbook. It was accepted fact.
Until it wasn't.
That name is Trained Immunity — and its discovery in 2011 by Professor Mihai Netea and colleagues at Radboud University may be one of the most consequential findings in modern biology.
The key to understanding trained immunity is epigenetics — the study of how genes are switched on and off without changing the underlying DNA sequence. Think of it like a dimmer switch on a lamp: the wiring is the same, but the brightness can be adjusted.
When an innate immune cell — like a monocyte or macrophage — encounters a threat for the first time, something remarkable happens beyond just fighting it off. The cell undergoes a series of chemical modifications to the proteins that DNA is wrapped around, called histones. These modifications physically open up specific regions of the genome, making key immune response genes easier to activate next time.
The cell doesn't store a record of what the threat was — not the way a T cell remembers a specific virus. Instead, it stores a readiness state. It becomes broadly primed. Faster. More potent. More alert.
This is trained immunity. And it can last for months — even, in some cases, years.
An innate immune cell meets a pathogen or stimulus — a fungal particle, a bacterial component, a vaccine. It mounts an immediate response, engulfing and destroying the threat. Standard procedure.
As the cell resolves the response, chemical marks are added to its histones — the proteins DNA is coiled around. Specifically, activating marks at H3K4me3 and H3K27ac positions open up regions near key immune genes, leaving them in a "ready" state. This is not random: these are the same genes that coordinate powerful immune responses.
Trained cells also shift their energy metabolism. They lean into aerobic glycolysis — a faster energy pathway that can fuel rapid activation. This rewiring is controlled by the same mTOR and HIF-1α pathways involved in cancer cell metabolism, hinting at deep biological connections.
Weeks or months later, the trained cell encounters a threat — any threat, even a completely different one. Because its key immune genes are already "open," activation is faster. Cytokine output is amplified. The response is stronger. The pathogen is cleared more efficiently.
Beta-glucan, a polysaccharide found in the cell walls of fungi and yeast, is one of the most potent known inducers of trained immunity. Found naturally in mushrooms, oats, and baker's yeast, it binds Dectin-1 receptors on monocytes and macrophages — triggering the epigenetic cascade. It is safe, non-toxic, and has been consumed by humans for millennia.
Perhaps the most striking discovery: trained immunity can be imprinted in hematopoietic stem cells in the bone marrow — the cells that generate all blood and immune cells. This means the training can propagate to every new innate immune cell produced for months. The body can be broadly primed at the source.
"We are now realizing that the innate immune system has more plasticity than we ever imagined. The implications are enormous."
— Prof. Mihai Netea, Radboud University Medical Center
Traditional vaccines target a single pathogen via adaptive immunity. Trained immunity vaccines could broadly prime the innate system — providing wider, faster protection against multiple threats simultaneously. BCG, originally developed for tuberculosis, reduces infant mortality from sepsis and respiratory infections by up to 50% through exactly this mechanism.
Tumor cells suppress the innate immune system to avoid detection. Trained immunity offers a route to re-arm innate cells against tumors. Early trials using beta-glucan as an adjunct to chemotherapy and immunotherapy show enhanced tumor clearance. The immune system's first responders, properly trained, may be potent cancer fighters.
During the COVID-19 pandemic, researchers found that BCG vaccination correlated with lower mortality rates in some populations — a trained immunity effect. Multiple clinical trials were launched. The possibility of broad-spectrum infectious disease protection through innate immune training is now actively pursued.
Trained immunity cuts both ways. Overactivation — when innate cells are trained to be hyperreactive — may drive chronic inflammation and autoimmune disease. Conditions like atherosclerosis, type 2 diabetes, and Alzheimer's may involve a form of maladaptive trained immunity. Understanding this opens new therapeutic targets to de-train an overactive innate system.
The discovery of trained immunity didn't invalidate what came before — it completed it. The innate immune system is not dumb. It is not stateless. It is a dynamic, adaptive, memory-capable system that we are only beginning to understand. The next generation of medicines, vaccines, and therapies will be built on this foundation.